Multiple Myeloma Hub | Quarter Four 2020 Update

The Multiple Myeloma Hub continues to be a platform that supports clinicians and healthcare providers by providing reliable up-to-date coverage of the latest developments within the field.

During this quarter, the Multiple Myeloma Hub attended a number of conferences. In October, live coverage was provided from the European School of Haematology (ESH) 5th Translational Research Conference: Multiple Myeloma, and the 6th World Congress on Controversies in Multiple Myeloma (COMy), with video interviews and reporting on social media channels.

The virtual Steering Committee meeting for the Multiple Myeloma Hub was held in November, which guides the direction of the hub for the next 6 months.

In December, the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition was held virtually for the first time and the Multiple Myeloma Hub provided extensive coverage through articles, live session reporting, and interviews with experts in the field. The new editorial theme, incidence and diagnosis of AL amyloidosis, was also introduced in December.

The Multiple Myeloma Hub showcases independent and credible evidence-based literature, drug approvals, case studies, international congress coverage, and expert opinions, and is brought to you by Scientific Education Support (SES). SES strives to build communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.

Guided by an international Steering Committee of world experts, and run in collaboration with the ESH, the Multiple Myeloma Hub is a global online resource that provides vital information for treatment teams, including hematologists and oncologists. Our mission is to provide up-to-date practical and clinical advice to community hematologists and oncologists, and ensure patients with multiple myeloma have access to the latest therapies available.

The Multiple Myeloma Hub would like to welcome its new industry partners Sanofi (Gold), and AbbVie (Silver), and would like to thank Roche/Genentech (Silver), Bristol Myers Squibb (Silver), GSK (Silver), Amgen (Bronze), and Karyopharm Therapeutics (Contributor), for their continued support of the platform.

For further information on the Multiple Myeloma Hub, please visit multiplemyelomahub.com.

For media enquiries or to explore collaboration opportunities, please contact